BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

MeSH terms

• Adaptor Proteins, Signal Transducing / biosynthesis*
• Antigens, CD34 / biosynthesis*
• Antineoplastic Agents / pharmacology*
• Antineoplastic Agents / therapeutic use
• Benzamides
• Flow Cytometry / methods
• Fusion Proteins, bcr-abl / biosynthesis*
• Fusion Proteins, bcr-abl / genetics*
• Gene Expression Regulation, Leukemic*
• Humans
• Imatinib Mesylate
• Inhibitory Concentration 50
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism*
• Models, Biological
• Nuclear Proteins / biosynthesis*
• Piperazines / therapeutic use
• Pyrimidines / therapeutic use
• Signal Transduction
• Treatment Outcome